Not every possible human who has the illness will buy the drug. I think we need to be realistic with our royalties estimates. It will take years to build up a large patient base, and even then will never hit 100% saturation.
Your argument is like giving Xero a valuation of a trilllion $ because every human on earth might need to do taxes.
Ann: Neuren Corporate Presentation, October 2019, page-80
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.42 |
Change
-0.190(1.22%) |
Mkt cap ! $1.991B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.37 | $2.634M | 168.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 125 | $15.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.43 | 267 | 7 |
View Market Depth
| Last trade - 12.34pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |